Harvard Bioscience (HBIO) Expected to Release Quarterly Earnings on Tuesday

Harvard Bioscience (NASDAQ:HBIO) is projected to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect Harvard Bioscience to announce earnings of ($0.21) per share and revenue of $21.45 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, August 11, 2026 at 8:00 AM ET.

Harvard Bioscience (NASDAQ:HBIO) last announced its quarterly earnings results on Tuesday, May 12th. The medical instruments supplier reported ($0.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.29. The firm had revenue of $20.75 million for the quarter, compared to the consensus estimate of $21.20 million. Harvard Bioscience had a negative net margin of 11.44% and a negative return on equity of 25.78%.

Harvard Bioscience Price Performance

Harvard Bioscience stock traded down $0.04 during midday trading on Tuesday, reaching $6.27. 1,361 shares of the stock were exchanged, compared to its average volume of 38,973. The firm has a market cap of $28.28 million, a PE ratio of -2.89 and a beta of 1.49. Harvard Bioscience has a 52 week low of $3.75 and a 52 week high of $9.40. The company’s fifty day moving average is $6.11 and its 200-day moving average is $5.80. The company has a debt-to-equity ratio of 3.60, a quick ratio of 1.06 and a current ratio of 1.99.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Harvard Bioscience in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $6.00.

Institutional Trading of Harvard Bioscience

Institutional investors have recently made changes to their positions in the stock. Bank of America Corp DE boosted its position in Harvard Bioscience by 44.4% during the 4th quarter. Bank of America Corp DE now owns 38,883 shares of the medical instruments supplier’s stock valued at $82,000 after buying an additional 11,948 shares during the period. XTX Topco Ltd bought a new stake in Harvard Bioscience during the 4th quarter valued at approximately $26,000. Goldman Sachs Group Inc. grew its stake in Harvard Bioscience by 291.9% in the fourth quarter. Goldman Sachs Group Inc. now owns 49,751 shares of the medical instruments supplier’s stock worth $33,000 after purchasing an additional 37,057 shares during the period. Virtu Financial LLC purchased a new stake in shares of Harvard Bioscience in the 4th quarter worth about $40,000. Finally, Jane Street Group LLC increased its stake in shares of Harvard Bioscience by 491.9% during the second quarter. Jane Street Group LLC now owns 70,736 shares of the medical instruments supplier’s stock valued at $31,000 after purchasing an additional 58,785 shares in the last quarter. Hedge funds and other institutional investors own 80.87% of the company’s stock.

About Harvard Bioscience

Harvard Bioscience, Inc develops, manufactures and distributes life science research instruments and consumables used by academic, biopharmaceutical and government laboratories worldwide. The company’s product portfolio spans cellular physiology, microfluidics, electrophysiology and lab automation, providing tools that enable researchers to study everything from cell behavior and organ function to drug delivery and tissue mechanics.

Through its operating units—most notably Harvard Apparatus, BTX, Radnoti and Warner Instruments—Harvard Bioscience offers a diverse range of scientific equipment including precision pumps, stereotaxic instruments, electroporation and gene delivery systems, perfusion systems and microinjection tools.